A recent study published in the journal Plastic and Reconstructive Surgery has found that patients who undergo “tummy tuck” surgery (abdominoplasty) to remove excess skin and tissue after weight loss continue to lose weight in the months and years after surgery. The study, which followed 188 patients for up to five years after their procedure, found that many of these individuals were able to achieve significant and sustained weight loss.

According to the researchers, who were led by Dr. John Y.S. Kim from Northwestern University Feinberg School of Medicine in Chicago, patients who underwent abdominoplasty surgery experienced an average weight loss of between five and six pounds at three to six months after their procedure. This weight loss continued over time, with an average loss of about five pounds between one and four years after surgery.

By the time of their five-year follow-up, patients had lost an average of nearly ten pounds, which is a significant reduction in body mass index (BMI). The researchers also found that about 60% of patients experienced weight loss during this period. Furthermore, they discovered that older patients, those who underwent liposuction or lipectomy at the same time as their abdominoplasty, and those who had never smoked were more likely to continue losing weight after surgery.

While the study’s findings are encouraging for individuals considering abdominoplasty surgery, it is essential to note that the researchers could not definitively explain why patients continued to lose weight after surgery. However, they suggested that patients may have developed healthy habits centered around nutrition and exercise that contributed to their long-term weight loss.

Overall, this study provides valuable new evidence that post-abdominoplasty weight reduction is a quantifiable phenomenon and highlights the need for further research into factors associated with sustained weight loss in patients who undergo abdominoplasty surgery.

Imagine the breathtaking landscapes of Arctic regions, where glaciers shimmer like diamonds and snow-capped mountains touch the sky. For structural biologist Kirill Kovalev, these frozen wonders are not just a sight to behold but also home to unusual molecules that could control brain cells’ activity.

Kovalev, an EIPOD Postdoctoral Fellow at EMBL Hamburg’s Schneider Group and EMBL-EBI’s Bateman Group, is passionate about solving biological problems. He has been studying rhodopsins, a group of colorful proteins found in aquatic microorganisms that enable them to harness sunlight. However, Kovalev’s discovery of cryorhodopsin proteins in Arctic microbes has opened up new avenues for research.

These extraordinary molecules have a unique dual function – they can sense UV light and pass on the signal to other parts of the cell. This property is unheard of among other rhodopsins, making cryorhodopsins truly remarkable. Kovalev’s team used advanced spectroscopy to show that cryorhodopsins are sensitive to UV light and can act as photosensors, allowing microbes to “see” this radiation.

The discovery of cryorhodopsins has raised hopes for new treatments in neuroscience. These proteins could potentially be used to develop optogenetic tools, which manipulate brain cells using light. This technology has the potential to revolutionize the treatment of neurological disorders such as Parkinson’s disease and epilepsy.

Kovalev’s journey to uncover the secrets of cryorhodopsins was not without its challenges. He had to overcome technical difficulties in studying these molecules at a microscopic level, using advanced techniques like 4D structural biology and protein activation by light. His team also had to work in almost complete darkness to prevent damage to the sensitive proteins.

Despite these hurdles, Kovalev’s discovery has sparked excitement in the scientific community. His unique approach to understanding cryorhodopsins has revealed the fascinating biology of these extraordinary molecules and their potential applications in neuroscience. As researchers continue to study cryorhodopsins, they may uncover even more secrets about how these proteins adapt to cold environments and what benefits they could hold for human health.

In conclusion, the discovery of cryorhodopsins is a groundbreaking achievement that has opened up new avenues for research in neuroscience. These extraordinary molecules have a unique dual function, allowing them to sense UV light and pass on the signal to other parts of the cell. As researchers continue to study these proteins, they may uncover even more secrets about their biology and potential applications in treating neurological disorders.

Cancer cells have a notorious ability to multiply rapidly and spread easily throughout the body. One of the reasons they are so successful is their ability to undergo a process called epithelial-to-mesenchymal plasticity, which makes them resistant to elimination by anticancer therapies. In an effort to find new ways to combat this resistance, researchers have been searching for newer anticancer agents that can target these “rogue” cancer cells.

A team of scientists led by Dr. Hideyuki Saya, Director of the Oncology Innovation Center at Fujita Health University in Japan, has made a groundbreaking discovery about the potential of benzaldehyde to halt therapy-resistant pancreatic cancer. This sweet-smelling molecule is responsible for the aroma of almonds, apricots, and figs, but it also has potent anticancer properties.

The researchers were driven by a desire to uncover the mechanism behind benzaldehyde’s anticancer effects, particularly after learning that one of their colleagues had demonstrated its potential back in the 1980s. The first author of the study, Dr. Jun Saito, was motivated by her parents’ pioneering work on benzaldehyde and its derivatives.

The team conducted extensive research using a mouse model grafted with growing pancreatic cancer cells. They found that benzaldehyde inhibited the growth of these cancer cells, even when they had become resistant to radiation therapy and treatment with osimertinib, an agent blocking tyrosine kinases in growth factor signaling.

Their findings revealed that benzaldehyde exerts its anticancer effects by preventing interactions between a key signaling protein called 14-3-3ζ and histone H3. This interaction is crucial for cancer cell survival and treatment resistance. By blocking this interaction, benzaldehyde reduced the expression of genes related to epithelial-mesenchymal plasticity.

The study also showed that benzaldehyde synergized with radiation therapy to eliminate previously resistant cancer cells. Furthermore, a derivative of benzaldehyde was found to inhibit the growth of pancreatic tumors and suppress epithelial-to-mesenchymal plasticity, preventing metastasis.

Dr. Saya’s team believes that their results suggest that inhibition of the interaction between 14-3-3ζ and its client proteins by benzaldehyde has the potential to overcome the problem of therapy resistance. This study opens up possibilities for using benzaldehyde as a combinatorial anticancer agent, alongside molecular-targeted therapies.

The implications of this research are significant, offering new hope for patients with therapy-resistant pancreatic cancer. Further studies will be necessary to confirm these findings and explore their potential applications in the clinic.